Described is the use of a safe and therapeutically effective amount of a combination of: (i) nebivolol or a pharmaceutically acceptable salt thereof; (ii) at least one hydralazine compound or a pharmaceutically acceptable salt thereof; and (iii) at least one of isosorbide dinitrate and/or isosorbide mononitrate; in the preparation if a medicament for improving NO release in a black patient, which results in reducing mortality associated with cardiovascular disease and improving exercise tolerance or the quality of life.
描述了安全且治疗有效量的以下物质组合的用途:(i)奈必洛尔或其药学上可接受的盐;(ii)至少一种水拉嗪化合物或其药学上可接受的盐;和(iii)二硝酸异山梨酯和/或单硝酸异山梨酯中的至少一种;用于制备改善黑人患者 NO 释放的药物,从而降低与心血管疾病相关的死亡率,改善运动耐受性或生活质量。